Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 2345 artículos Viendo del 1 al 40 de 2345 artículos
Pub MED

The prevalence of early repolarization in Wolff-Parkinson-White syndrome with a special reference to J waves and the effects of catheter ablation.NUEVO

Yagihara N, Sato A, Iijima K, Izumi D, Furushima H, Watanabe H, Irie T, Kaneko Y, Kurabayashi M, Chinushi M, Satou M, Aizawa Y.
J Electrocardiol. 2012 Jan-Feb;45(1):36-42. doi: 10.1016/j.jelectrocard.2011.04.006.
Pub MED

Computed tomography of a coronary sinus diverticulum associated with Wolff-Parkinson-White syndrome.NUEVO

Morin DP, Parker H, Khatib S, Dinshaw H.
Heart Rhythm. 2012 Aug;9(8):1338-9. doi: 10.1016/j.hrthm.2011.05.004. No abstract available.
Pub MED

Surgical outcome of lumbar fusion surgery in patients with Parkinson disease.NUEVO

Moon SH, Lee HM, Chun HJ, Kang KT, Kim HS, Park JO, Moon ES, Chong HS, Sohn JS, Kim HJ.
J Spinal Disord Tech. 2012 Oct;25(7):351-5.
Pub MED

The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study.NUEVO

Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG.
Neurosurgery. 2012 Jan;70(1):18-23; discussion 23-4. doi: 10.1227/NEU.0b013e3182266664.
Pub MED

Prevalence of psychotic symptoms in a community-based Parkinson disease sample.NUEVO

Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Williams JR, Marsh L.
Am J Geriatr Psychiatry. 2012 Feb;20(2):123-32. doi: 10.1097/JGP.0b013e31821f1b41.
Pub MED

Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.NUEVO

Lee MJ, Wang K, Kim IS, Lee BH, Han HS.
Mol Imaging Biol. 2012 Apr;14(2):147-55. doi: 10.1007/s11307-011-0497-z.
Pub MED

Synaptic vesicle trafficking and Parkinson's disease.NUEVO

Esposito G, Ana Clara F, Verstreken P.
Dev Neurobiol. 2012 Jan;72(1):134-44. doi: 10.1002/dneu.20916. Review.
Pub MED

The use of echocardiography in Wolff-Parkinson-White syndrome.NUEVO

Cai Q, Shuraih M, Nagueh SF.
Int J Cardiovasc Imaging. 2012 Apr;28(4):725-34. doi: 10.1007/s10554-011-9880-8. Review.
Pub MED

Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital.NUEVO

Bloomfield K, MacDonald L, Finucane G, Snow B, Roxburgh R.
Intern Med J. 2012 Jul;42(7):e151-6. doi: 10.1111/j.1445-5994.2011.02499.x.
Pub MED

Immunology, autoimmunity, and autoantibodies in Parkinson's disease.NUEVO

Benkler M, Agmon-Levin N, Hassin-Baer S, Cohen OS, Ortega-Hernandez OD, Levy A, Moscavitch SD, Szyper-Kravitz M, Damianovich M, Blank M, Chapman J, Shoenfeld Y.
Clin Rev Allergy Immunol. 2012 Apr;42(2):164-71. doi: 10.1007/s12016-010-8242-y.
Pub MED

Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson's disease.NUEVO

Reimers D, Osuna C, Gonzalo-Gobernado R, Herranz AS, Diaz-Gil JJ, Jimenez-Escrig A, Asensio MJ, Miranda C, Rodriguez-Serrano M, Bazan E.
Curr Stem Cell Res Ther. 2012 Jan;7(1):15-25.
Pub MED

Successful stenting of a left main coronary artery occlusion as a complication of RF ablation for Wolff-Parkinson-White syndrome.NUEVO

Yalin K, Golcuk E, Bilge AK, Umman S, Adalet K.
Pacing Clin Electrophysiol. 2012 Feb;35(2):e43-6. doi: 10.1111/j.1540-8159.2010.02900.x.
Pub MED

DNA repair genes in Parkinson's disease.NUEVO

Gencer M, Dasdemir S, Cakmakoglu B, Cetinkaya Y, Varlibas F, Tireli H, Kucukali CI, Ozkok E, Aydin M.
Genet Test Mol Biomarkers. 2012 Jun;16(6):504-7. doi: 10.1089/gtmb.2011.0252.
Pub MED

Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?NUEVO

Pignatti R, Brioschi A, Mauro A, Zamarian L, Wenter J, Semenza C.
Neurocase. 2012;18(6):503-13. doi: 10.1080/13554794.2011.633529.
Pub MED

[A challenge towards the clinical application of induced pluripotent stem cell technology for the treatment of Parkinson's disease].NUEVO

Morizane A, Takahashi J.
Brain Nerve. 2012 Jan;64(1):29-37. Review. Japanese.
Pub MED

Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease.NUEVO

Michelakakis H, Xiromerisiou G, Dardiotis E, Bozi M, Vassilatis D, Kountra PM, Patramani G, Moraitou M, Papadimitriou D, Stamboulis E, Stefanis L, Zintzaras E, Hadjigeorgiou GM.
Mov Disord. 2012 Mar;27(3):400-5. doi: 10.1002/mds.24886.
Pub MED

Taking sides: is handedness involved in motor asymmetry of Parkinson's disease?NUEVO

Melamed E, Poewe W.
Mov Disord. 2012 Feb;27(2):171-3. doi: 10.1002/mds.24048. No abstract available.
Pub MED

Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.NUEVO

McCorvy JD, Watts VJ, Nichols DE.
Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5.
Pub MED

Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.NUEVO

Navailles S, De Deurwaerdère P.
Mol Neurobiol. 2012 Feb;45(1):173-85. doi: 10.1007/s12035-011-8230-0. Review.
Pub MED

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.NUEVO

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E.
Clin Neuropharmacol. 2012 Jan-Feb;35(1):15-20. doi: 10.1097/WNF.0b013e318241520b.
Pub MED

Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.NUEVO

Gershanik O, Jenner P.
Eur J Neurol. 2012 Dec;19(12):1502-8. doi: 10.1111/j.1468-1331.2011.03593.x. Review.
Pub MED

Updates in the medical management of Parkinson disease.NUEVO

Fernandez HH.
Cleve Clin J Med. 2012 Jan;79(1):28-35. doi: 10.3949/ccjm.78gr.11005. Review.
Pub MED

Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.NUEVO

Kim K, Kim SH, Kim J, Kim H, Yim J.
J Biol Chem. 2012 Feb 24;287(9):6628-41. doi: 10.1074/jbc.M111.291179.
Pub MED

Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.NUEVO

Minelli A, Conte C, Cacciatore I, Cornacchia C, Pinnen F.
Amino Acids. 2012 Sep;43(3):1359-67. doi: 10.1007/s00726-011-1210-x.
Pub MED

Nonmotor manifestations in Parkinson disease.NUEVO

Bernal-Pacheco O, Limotai N, Go CL, Fernandez HH.
Neurologist. 2012 Jan;18(1):1-16. doi: 10.1097/NRL.0b013e31823d7abb. Review.
Pub MED

Clinical application of stem cell therapy in Parkinson's disease.NUEVO

Politis M, Lindvall O.
BMC Med. 2012 Jan 4;10:1. doi: 10.1186/1741-7015-10-1. Review.
Pub MED

Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome: results of a prospective long-term electrophysiological follow-up study.NUEVO

Pappone C, Vicedomini G, Manguso F, Baldi M, Pappone A, Petretta A, Vitale R, Saviano M, Ciaccio C, Giannelli L, Calovic Z, Tavazzi L, Santinelli V.
Circulation. 2012 Feb 7;125(5):661-8. doi: 10.1161/CIRCULATIONAHA.111.065722.
Pub MED

Risk of sudden death in Wolff-Parkinson-White syndrome: how high is the risk?NUEVO

Obeyesekere M, Gula LJ, Skanes AC, Leong-Sit P, Klein GJ.
Circulation. 2012 Feb 7;125(5):659-60. doi: 10.1161/CIRCULATIONAHA.111.085159. No abstract available.
Pub MED

The relationship of depression and disease stage to patient perceptions of Parkinson's disease.NUEVO

Hurt CS, Weinman J, Lee R, Brown RG.
J Health Psychol. 2012 Oct;17(7):1076-88. doi: 10.1177/1359105311428537.
Pub MED

Predictors of survival in patients with Parkinson disease.NUEVO

Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA.
Arch Neurol. 2012 May;69(5):601-7.
Pub MED

Curcumin: a potential neuroprotective agent in Parkinson's disease.NUEVO

Mythri RB, Bharath MM.
Curr Pharm Des. 2012;18(1):91-9. Review.
Pub MED

Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson's disease.NUEVO

Gadad BS, Subramanya PK, Pullabhatla S, Shantharam IS, Rao KS.
Curr Pharm Des. 2012;18(1):76-84.
Pub MED

Investigational agents in the treatment of Parkinson's disease: focus on safinamide.NUEVO

Malek NM, Grosset DG.
J Exp Pharmacol. 2012 Aug 14;4:85-90. doi: 10.2147/JEP.S34343. Review.
Pub MED

Concurrence of Frailty and Parkinson's Disease.NUEVO

Roland KP, Cornett KM, Theou O, Jakobi JM, Jones GR.
J Frailty Aging. 2012;1(3):123-7. doi: 10.14283/jfa.2012.20.
Pub MED

Management of Parkinson's Disease medication in acutely admitted patients.NUEVO

Sathyababu R, Chan E, Dhakam Z.
BMJ Qual Improv Rep. 2012 Oct 24;1(1). pii: u473.w154. doi: 10.1136/bmjquality.u473.w154.
Pub MED

Improving Compliance with NICE Guidelines on Parkinson's isease: A Quality Improvement Study.NUEVO

Agha R, Edison E, Fielder Camm C, Cheng L, Gajendragadkar P, Borland C.
Ann Med Surg (Lond). 2012 Aug 9;1:34-8. doi: 10.1016/S2049-0801(12)70011-0.
Pub MED

Increasing the Detection Limit of the Parkinson Disorder through a Specific Surface Chemistry Applied onto Inner Surface of the Titration Well.NUEVO

Mille C, Debarnot D, Zorzi W, El Moualij B, Coudreuse A, Legeay G, Quadrio I, Perret-Liaudet A, Poncin-Epaillard F.
J Funct Biomater. 2012 Apr 18;3(2):298-312. doi: 10.3390/jfb3020298.
Pub MED

Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.NUEVO

Fiandaca MS, Bankiewicz KS, Federoff HJ.
Pharmaceuticals (Basel). 2012 Jun 4;5(6):553-90. doi: 10.3390/ph5060553.
Pub MED

Cognitive impairments in Parkinson's disease: Evidence from an Iranian population.NUEVO

Ashrafi F, Zali A, Pakdaman H, Johari K.
Iran J Neurol. 2012;11(4):151-4.
Pub MED

A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming.NUEVO

Ponsen MM, Stam CJ, Bosboom JL, Berendse HW, Hillebrand A.
Neuroimage Clin. 2012 Nov 17;2:95-102. doi: 10.1016/j.nicl.2012.11.007.
Viendo del 1 al 40 de 2345 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.